Cell line resources for COVID-19 research

1) Efforts of RIKEN BRC promoting COVID-19 related research

RIKEN BioResource Research Center (BRC) is a unique repository in the world, as it collects and distributes bioresources of three different levels, i.e., genetic materials (genomic and cDNA clones) and cell lines of human and animal origins as well mouse strains. With this unique feature, RIKEN BRC hopes to contribute to the comprehensive research and development on COVID-19. The research and developments have been focusing on the following four subjects: 1) SARS-CoV-2 infection and proliferation, 2) Pathogenesis and host defense, 3) Disease progression to clinically severe cases and 4) Development of effective therapies of COVID-19 patients and preventive vaccines against SARS-CoV-2 infection.

Lists of mouse strains and DNA clones useful for COVID-19 R&D from RIKEN BRC are available from following links:

Mouse resources for COVID-19 research. (Experimental Animal Division)

Human genes for COVID-19 research. (Gene Engineering Division)


2)Deposited cell lines

ReferenceBRC ResourceComment
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection NEWRCB5391 R52_Spike This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone R52).
RCB5392 S1D7_Spike This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S1D7).
RCB5393 S3D8_Spike This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S3D8).

3) Papers regarding COVID-19 research in which the cell lines we have provided were used.

BRC ResourceReference
1RCB2202 293T Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry
2RCB0995 MDCK Clin Infect Dis. 2020 Oct 3;ciaa1517Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19
3RCB0535 RAW 264 Viruses. 2020 Jun 28;12(7):699Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2
4RCB0988 CACO-2
CSII-CMV-MCS-IRES2-Bsd
PLoS Pathog. 2021 Jan 21;17(1):e1009233.SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
5RCB0485 LA-N-5 Sci Rep. 2021 Feb 9;11(1):3379Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
6RCB2202 293T Cell. 2021 Jun 24;184(13):3452-3466.e18An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
7RCB1902 HSC-4 J Anat. 2021 Jun;238(6):1341-1354Expression of SARS‐CoV‐2 entry factors in human oral tissue
8RCB0209 SP2/0-Ag14 J Biol Chem. Jan-Jun 2021;296:100346 Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
9RCB0988 CACO-2
RCB2202 293T
Sci Rep. 2021 Mar 8;11(1):5376 MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
10RCB0098 A549 bioRxiv. June 30, 2021. Host cellular RNA helicases regulate SARS-CoV-2 infection
11RCB0211 MRC-5Cell Rep Med. 2021 Jun 15;2(6):100311 Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
12NEWRCB2202 293TbioRxiv. August 23, 2021The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
13NEWRCB0098 A549 Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells
14NEWHPS0002 253G1 J Toxicol Sci
. 2021;46(9):425-435
Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing

4) Papers regarding COVID-19 research in which the cell lines we can provide were used.

BRC Cell LineCell LineReference
1Vero E6
RCB0988 CACO-2
Calu-3
RCB2202 293T
RCB1366 HuH-7
Vero E6
Caco-2
Calu-3
HEK293T
Huh7
In Vitro and Animal Models for SARS-CoV-2 research
2Vero E6
RCB1366 HuH-7
RCB2202 293T
RCB0098 A549, RCB3677 A549
EFKB3
Vero E6
Vero
HUH 7.0
293T
A549
EFKB3
Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
3Vero
RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1366 HuH-7
Vero
HeLa
HEK293T/F
Huh7
A Thermostable mRNA Vaccine against COVID-19
4RCB1637 293
RCB2202 293T
RCB0098 A549, RCB3677 A549
RCB0218 MRC-5, known PDL
Vero E6
Vero 81
RCB0007 HeLa, RCB3680 HeLa
RCB1366 HuH-7
293
293T
A549
MRC5
Vero E6
Vero 81
HeLa
Huh7
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
5RCB1648 Hep G2
RCB1366 HuH-7
RCB2202 293T
Vero
CHO
RCB0995 MDCK
HepG2
Huh-7
293T
Vero
CHO
MDCK
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
6Vero E6
RCB1366 HuH-7
Vero E6
Huh-7
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
7Vero E6
RCB1366 HuH-7
Vero E6
Huh-7
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
8Vero E6
RCB1366 HuH-7
Vero E6
Huh-7
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
9Vero E6
RCB1366 HuH-7
Vero E6
Huh-7
A pneumonia outbreak associated with a new coronavirus of probable bat origin
10RCB1637 293
RCB1366 HuH-7
RCB1423 BHK-21
Vero E6
HEK293
Huh-7
BHK21
Vero-E6
Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε
11RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1423 BHK-21
RCB0988 CACO-2
HeLa
293T
BHK-21
Caco-2
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
12RCB0988 CACO-2Caco-2Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
13RCB0988 CACO-2Caco-2A metabolic handbook for the COVID-19 pandemic
14RCB2202 293T
RCB0098 A549, RCB3677 A549
BHK
RCB0988 CACO-2
RCB1366 HuH-7
PK-15
293T
A549
BHK
Caco-2
Huh-7.5
PK-15
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
15RCB2202 293T
RCB0098 A549, RCB3677 A549
HEK293T
A549
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
16RCB2202 293T
RCB0007 HeLa, RCB3680 HeLa
Calu-3
RCB0218 MRC-5, known PDL
HEK293T
HeLa
Calu-3
MRC-5
Cell entry mechanisms of SARS-CoV-2
17RCB2202 293T
HEK293F
RCB0007 HeLa, RCB3680 HeLa
RCB0218 MRC-5, known PDL
HEK293T
HEK293F
HeLa
MRC5
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
18RCB1366 HuH-7
Huh-7.5
Huh-7
Huh-7.5
Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
19MA104
RCB1637 293
MA104
HEK293
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
20RCB0218 MRC-5, known PDL MRC-5 Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
21Fcwf-4
A72
RCB0995 MDCK
DH82
Fcwf-4
A72
MDCK
DH82
Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663
22GES-1
RCB1189 THP-1,RCB3686 THP-1
GES-1
THP-1
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels


Comments are closed.